Akeso CEO Michelle Xia on ivonescimab's biliary tract cancer OS win, ESMO plans and defending HARMONi-6's 0.72 PFS hazard ratio.
For Akeso CEO Michelle Xia, the intense spotlight on her company and its PD-1xVEGF bispecific ivonescimab still feels new, despite several years in the headlines …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial
Chinese cancer treatment shows survival edge in trial
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Fierce Pharma Asia—Roche’s $2.5B obesity deal; Akeso CEO’s defense; Lawmaker’s reflection on China
Why Is Summit Therapeutics Stock Soaring Today? - Summit Therapeutics (NASDAQ:SMMT)
As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground
Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody…
Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major Phase 3…
Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined…
